Qyuns Therapeutics Co., Ltd.
2509.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.8B
Close$
Share Statistics
| Market cap | $3.80 Billion |
|---|---|
| Enterprise Value | $4.16 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.37 |
| Beta | 1.47 |
| Outstanding Shares | 224,534,398 |
Return
| Return on Equity | 63.42% |
|---|---|
| Return on Assets | 28.58% |
| Return on Invested Capital | 41.51% |
Valuation & Multiples
| P/E Ratio | 5.98 |
|---|---|
| PEG | -0.73 |
| Price to Sales | 4.11 |
| Price to Book Ratio | 5.47 |
| Enterprise Value to Revenue | 4.06 |
| Enterprise Value to EBIT | 7.54 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.8 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 26, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Qyuns Therapeutics Co., Ltd.
337 employees
CEO: Jiwan Qiu Qyuns Therapeutics Co., Ltd., a biotechnology company established in 2015 and headquartered in Taizhou, China, is focused on the discovery and clinical advancement of biologic therapies. Its primary mission is to address autoimmune and a...